Only Eurofins NTD, LLC. measures free Beta hCG and acheives: Detection Rate: 95%. False Positive: 2%
for Down syndrome

First Trimester Screen | Fß with Fetal Nasal Bone Assessment

Provides a 96% detection rate at a 2% false positive rate for Down syndrome

Research shows that the fetal nasal bone is absent in approximately 70% of all Down syndrome cases. With the Fetal Nasal Bone Assessment option added to the First Trimester Screen | Fβ protocol, physicians can raise the detection rate for Down syndrome to 96% and virtually eliminate the need to screen for Down syndrome beyond the first trimester.

(References 25, 36)

Fetal Nasal Bone Assessment is a non-invasive procedure that helps provide even greater assurance to patients undergoing their first trimester risk assessment for Down syndrome. It is performed during the patient's NT ultrasound examination so there are no additional patient visits required as a result of electing this option. Physicians and sonographers must be credentialed in fetal nasal bone assessment to select this option. In part, this credentialing can be achieved by attending a one day seminar, which may also qualify for CME credits.

The benefits of Fetal Nasal Bone Assessment:

  • Raises the Down syndrome detection rate to 96% while maintaining all of the screening in the first trimester
  • Offers a 2% false positive rate vs. a 5% false positive rate

(References 25, 36)

DISCLAIMER: This test is a part of a lab service offering provided by Eurofins NTD, LLC. This test was developed and its performance characteristics determined by Eurofins NTD, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health. The test results do not eliminate the possibility that this pregnancy may be associated with birth defects or pregnancy complications including preeclampsia, pre-term delivery and low birth weight. The multiple of the median and risk results provided in the test report are dependent on the accuracy of the demographic and ultrasound information provided. The ordering physician should ensure that the ultrasound information has been obtained from a sonographer who is credentialed by and participating in a uterine artery Doppler quality review program such as FMF. Eurofins NTD, LLC. assumes no responsibility for ensuring that the ultrasound information has been obtained by a properly credentialed sonographer, including verification or updates to credentialing status.